Inotrem

Executive Summary

Inotrem is a French biotechnology company founded in 2013 that specializes in immunotherapies targeting the TREM-1 pathway, a key modulator of the inflammatory response. The company's lead candidate, nangibotide (LR12), is being developed for acute inflammatory conditions, including septic shock and COVID-19-related complications. Inotrem has reported positive Phase 2 results for nangibotide in septic shock, showing a significant reduction in mortality in a subgroup of patients with high TREM-1 levels. The company is now advancing a Phase 3 trial in septic shock and exploring the potential of its platform in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. With a novel mechanism of action and a strong scientific foundation, Inotrem is positioned as a promising player in the immunology space, though it remains in the clinical stage with no approved products yet.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line results for nangibotide in septic shock70% success
• Q4 2026Initiation of Phase 2 trial in rheumatoid arthritis60% success
• Q2 2026Partnership or licensing deal for TREM-1 platform50% success